系统性红斑狼疮疾病活动度评分缓解与低疾病活动度状态可区分药物与安慰剂并关联更好的健康相关生活质量
该研究为BLISS-52与BLISS-76试验数据的事后汇总分析,评估SLE-DAS缓解和低疾病活动度(LDA)区分贝利尤单抗与安慰剂及区分健康相关生活质量(HR-QoL)的能力。第52周时,贝利尤单抗1 mg/kg和10 mg/kg组达到SLE-DAS LDA的患者比例均显著高于安慰剂组,10 mg/kg组达到SLE-DAS缓解的比例也显著高于安慰剂组。达到SLE-DAS缓解或LDA的患者SF-36和FACIT-F评分更高,自基线改善更显著。
要点
- 第52周贝利尤单抗1 mg/kg组SLE-DAS LDA达标率17.9% vs 安慰剂组13.0%(P=0.023;OR 1.459;RR 1.377;NNT 20.4)。
- 第52周贝利尤单抗10 mg/kg组SLE-DAS LDA达标率21.7% vs 安慰剂组13.0%(P<0.001;OR 1.853;RR 1.668;NNT 11.5)。
- 第52周贝利尤单抗10 mg/kg组SLE-DAS缓解率14.7% vs 安慰剂组10.1%(P=0.019;OR 1.532;RR 1.454;NNT 21.7)。
核心结论
- SLE-DAS缓解和LDA在SLE临床试验中能够区分接受活性药物的患者。
- 达到这些SLE-DAS目标与更好的健康相关生活质量相关。
研究设计与样本
- 该研究为BLISS-52(NCT00424476)和BLISS-76(NCT00410384)试验数据的汇总事后分析。
- 采用卡方检验比较第52周贝利尤单抗与安慰剂组间SLE-DAS缓解和LDA的达标率及区分能力。
- 采用t检验和Mann-Whitney检验比较第52周达到与未达到SLE-DAS缓解或LDA患者的SF-36和FACIT-F评分。
- 采用校正基线评分的多变量回归分析比较组间第0周至第52周SF-36和FACIT-F评分的平均变化。
主要发现
- 第52周贝利尤单抗1 mg/kg组SLE-DAS LDA达标率17.9% vs 安慰剂组13.0%(P=0.023;OR 1.459;RR 1.377;NNT 20.4)。
- 第52周贝利尤单抗10 mg/kg组SLE-DAS LDA达标率21.7% vs 安慰剂组13.0%(P<0.001;OR 1.853;RR 1.668;NNT 11.5)。
- 第52周贝利尤单抗10 mg/kg组SLE-DAS缓解率14.7% vs 安慰剂组10.1%(P=0.019;OR 1.532;RR 1.454;NNT 21.7)。
- 第52周达到SLE-DAS缓解和LDA的患者SF-36各领域及汇总评分更高(所有P<0.001),FACIT-F评分也更高(两者P<0.001)。
- 达到SLE-DAS缓解和LDA的患者自基线至第52周SF-36和FACIT-F评分的平均改善显著更高。
关键数值与推荐
- SLE-DAS LDA达标率:贝利尤单抗1 mg/kg组17.9% vs 安慰剂组13.0%(P=0.023;OR 1.459;RR 1.377;NNT 20.4)。
- SLE-DAS LDA达标率:贝利尤单抗10 mg/kg组21.7% vs 安慰剂组13.0%(P<0.001;OR 1.853;RR 1.668;NNT 11.5)。
- SLE-DAS缓解达标率:贝利尤单抗10 mg/kg组14.7% vs 安慰剂组10.1%(P=0.019;OR 1.532;RR 1.454;NNT 21.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to evaluate the ability of Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) remission and low disease activity (LDA) to discriminate active drug from placebo and to discriminate outcomes in the patients' perspective (health-related quality of life [HR-QoL]) in SLE trials. METHODS: This was a post hoc analysis of the pooled Belimumab in Subjects With SLE (BLISS)-52 (NCT00424476) and BLISS-76 (NCT00410384) trials data. SLE-DAS remission and LDA attainment and discrimination between belimumab and placebo at 52 weeks were compared using chi-square tests. At week 52, 36-item Short Form Health Survey (SF-36) and Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) scores were compared between patients attaining SLE-DAS remission versus nonremission and SLE-DAS LDA versus non-LDA using the t-test and Mann-Whitney test. Mean changes from week 0 to 52 in SF-36 and FACIT-F scores were compared between groups using multivariate regression analysis adjusted for baseline scores. RESULTS: At week 52, significantly more patients attained SLE-DAS LDA taking belimumab 1 mg/kg (17.9% vs 13.0%; P = 0.023; odds ratio [OR] 1.459; relative risk [RR] 1.377; number needed to treat [NNT] 20.4) and 10 mg/kg (21.7% vs 13.0%; P < 0.001; OR 1.853; RR 1.668; NNT 11.5) compared with placebo. Likewise, more patients attained SLE-DAS remission taking belimumab 10 mg/kg compared to placebo (14.7% vs 10.1%; P = 0.019; OR 1.532; RR 1.454; NNT 21.7). At week 52, patients attaining SLE-DAS remission and LDA presented higher SF-36 domain and summary scores (all P < 0.001) and FACIT-F scores (both P < 0.001). Mean improvements from baseline in SF-36 and FACIT-F scores were significantly higher in patients achieving SLE-DAS remission and LDA. CONCLUSION: SLE-DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE-DAS targets are associated with better HR-QoL.
引用
- Jesus D, Henriques C, Matos A, et al. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life. Arthritis Care Res (Hoboken). 2024. PMID: 38258369. doi:10.1002/acr.25305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。